Resources

Country- and Community-Led Scale-Up of Accessible, Integrated, and Family-Centered EVT Plus Services for a Healthy Start (SAFEStart+)While childhood survival rates have significantly improved in the past decade, every year, approximately five million children die before their fifth birthday—almost half are newborns in their first month of life. Vertical transmission of HIV, syphilis, hepatitis B, and Chagas disease is a leading cause of preventable stillbirth and child mortality. Timely diagnosis and treatment of these infections are critical to protect the health and well-being of women, infants, and young children.Through partnership and funding from Unitaid, PATH and the project’s co-leads, the International Community of Women living with HIV Eastern Africa and the World Hepatitis Alliance, are leading a four-year project designed for maximum reach and impact: SAFEStart+. This project is accelerating demand and adoption of evidence-based approaches and integrated delivery strategies to eliminate vertical transmission of HIV, syphilis, hepatitis B, and Chagas disease.SAFEStart+ is supporting countries and communities to design and scale integrated, people-centered services that meet local needs. This includes expanding access to new diagnostics that can detect multiple infections with a single test and reinforcing antenatal care services to deliver preventive treatment when it matters most.

This is a simple, Excel-based tool for assessing and comparing costs of respiratory syncytial virus (RSV) intervention programs annually and for a period of five years with RSV maternal vaccine and monoclonal antibody (mAb) products available in the global market.It aims to help country-level policymakers compare products and estimate intervention program costs for both RSV maternal vaccine and mAbs. The tool can be used by decision-makers, implementers, technical partners, and others in any country, whether or not the country is eligible for co-funding from Gavi, the Vaccine Alliance.Product cost estimates (i.e., supplies procurement and international shipping) and immunization program costs (i.e., cost of delivery) are calculated separately for two perspectives: (1) the country perspective and (2) the combined country and donor/Gavi perspective (only relevant for Gavi-eligible countries). The tool also calculates the estimated cold chain volume requirements, which can support operational planning and logistics.It's important to note that cost is only one consideration when selecting an RSV intervention product, and users involved in decision-making around new vaccine introduction or product selection should always consider other dimensions as well. This model is meant to provide insights into the potential costs of alternative product choices and should not replace detailed budget planning once a product has been selected.A user guide is included in the file on a tab labeled “READ ME FIRST” which provides detailed instructions on how to use the tool and interpret the results. Please be sure to check out this seven-minute tutorial video, which is in English, with French and Spanish subtitled versions also available. The tool is available to download in multiple languages below. For questions or support, contact PATH’s Health Economics & Outcomes Research Team: HEOR@path.org.

This slide provides a snapshot of the respiratory syncytial virus (RSV) vaccine and monoclonal antibody (mAb) technology landscape, in the effort to track the development of RSV vaccine and mAb candidates and provide a summary of the various vaccine approaches being worked on around the world.This snapshot pairs with the RSV and mAb Trial Tracker, which provides publicly available information on clinical trials of RSV candidate vaccines and mAbs intended for prevention.To share any updates or corrections to the snapshot, please contact rsvsnapshot@path.org.

This spreadsheet provides publicly available information on clinical trials of respiratory syncytial virus (RSV) candidate vaccines and monoclonal antibodies intended for prevention.Sources of information for these trials are clinicaltrials.gov; who.int/clinical-trials-registry-platform; clinicaltrialsregister.eu; and anzctr.org.au, which includes clinical trial registries from 17 countries.Some information is also obtained through contact with investigators, sponsors, and funders of vaccine trials. This spreadsheet pairs with the RSV Vaccine and mAb Snapshot, which provides a summary of the RSV vaccine and mAb candidates in development worldwide.To share any updates or corrections to the tracker, please contact rsvsnapshot@path.org.

In the Democratic Republic of the Congo (DRC), community care sites (CCS) are small health posts stationed across the country and run by two community health workers. The CCS are used to bring essential health care to hard to reach communities, especially those without an accessible health facility.PATH's Malaria Control and Elimination Partnership in Africa (MACEPA) and Rotary Healthy Communities Challenge (RHCC) teams collaborated to apply geospatial modeling to recommend strategic placement of CCS to the DRC Ministry of Health.Learn more about this process and the work in the brief below.